key: cord-0892419-9ky8s7v5
authors: Lam, M.; Egail, M.; Bedlow, A. J.; Tso, S.
title: Ribonucleic acid COVID‐19 vaccine‐associated cutaneous adverse drug events: a case series of two patients
date: 2021-05-10
journal: Clin Exp Dermatol
DOI: 10.1111/ced.14673
sha: 6610499175bef22ef5e2f07f76c7e1753691563f
doc_id: 892419
cord_uid: 9ky8s7v5

Vaccines are biological preparations that enable their recipients to acquire immunity to a specific infectious disease. All vaccines can associate with cutaneous adverse drug events. Ribonucleic acid (RNA) vaccine was first tested in humans in COVID-19 prevention trials in 2020. The Pfizer-BioNTech COVID-19 vaccine utilises lipid nanoparticles, which act as a vector for the embedded mRNA. In a phase III clinical trial, it was found that local reactions at the injection site are the commonest side effect (84.7%). Other adverse reactions included fatigue, headache, muscle ache, chills, joint pain and fever.1 Jedlowski and Jedlowski (2021) reported a case of recurrent morbilliform rash that developed 48 hours following administration of the Pfizer-BioNTech COVID-19 vaccine on two separate occasions, 21 days apart.2 We hereby report two patients presented with cutaneous adverse drug events following RNA vaccination (Pfizer-BioNTech COVID-19 vaccine).

Vaccines are biological preparations that enable their recipients to acquire immunity to a specific infectious disease. All vaccines can be associated with cutaneous adverse drug events (ADEs). The new ribonucleic acid (RNA) vaccine type developed by Pfizer-BioNTech was first tested in humans in COVID-19 prevention trials in 2020. This vaccine utilizes lipid nanoparticles, which act as a vector for the embedded mRNA. In a phase III clinical trial, it was found that local reactions at the injection site are the commonest side effect (84.7%), with other adverse reactions including fatigue, headache, muscle ache, chills, joint pain and fever. 1 A recent report described a case of recurrent morbilliform rash that developed 48 h following administration of the Pfizer-BioNTech COVID-19 vaccine on two separate occasions, 21 days apart. 2 We report two patients who presented with cutaneous ADEs following this vaccine.

In brief, both patients were systemically well with no COVID-19 or infection symptoms prior to their COVID-19 vaccinations and the onset of their skin rash. The patients' clinical characteristics, investigation results and management are presented in Table 1 . 

Patient 1 was a 60-year-old woman who developed a rash 2 weeks following vaccination. She presented to Dermatology 2 days later with a widespread symmetrical erythematous and purpuric eruption predominantly affecting her legs (Fig. 1a) . Skin biopsies were obtained from the nonpurpuric rash and perilesional skin on her right thigh; histology showed eosinophils and the direct immunofluorescence microscopy result was negative. The rash gradually improved after 7 days of oral prednisolone and topical treatments (Fig. 1b) .

Patient 2 was a 75-year-old woman, who developed a confluent erythematous rash on her torso (Fig. 2a) and a   (a) (b) Figure 1 (a,b) A 60-year-old woman with a widespread symmetrical erythematous and purpuric rash predominantly affecting her legs: (a) rash at day 5 as she was commenced on treatment and (b) resolving rash is at day 17.

(a) (b) (c) Figure 2 (a,b) A 75-year-old woman with (a) a confluent erythematous rash on trunk (b) and a symmetrical purpuric rash over the gaiter areas of her legs at day 3; (c) complete resolution of the rash at day 10.

ª 2021 British Association of Dermatologists symmetrical purpuric rash over the gaiter areas of her legs (Fig. 2b) , 2 days following vaccination. She had no history of lower limb chronic venous insufficiency. The primary care team commenced her on oral prednisolone for 5 days. A skin biopsy was not taken. The rash was fully resolved by day 10 (Fig. 2c) . The patient did not experience any ADE following the second Pfizer-BioNTech COVID-19 vaccine. We report two cases of post-RNA vaccination associated generalized rash with no systemic involvement. To date, the exact mechanism of vaccine-associated cutaneous ADEs remain poorly characterized. 3 It is possible that the whole class of RNA vaccines may share a similar cutaneous ADE profile to that of live and inactivated vaccines. Our patients' presentation of a purpuric rash on the legs raised the possibility of cutaneous small vessel vasculitis, although the clinical indications were not confirmed by skin biopsy. Vaccine-associated cutaneous vasculitis is a rare event. Bonetto et al. reported influenza vaccination as the vaccine type most likely to trigger vasculitis, particularly the cutaneous vasculitis subtype. 4 Our case series suggest that the mechanism of vaccine-associated cutaneous ADEs may not be dependent upon vaccine uptake by antigen-presenting cells, as is the case for live or inactivated vaccines. Understanding downstream transcriptomics-related events following drug administration (including vaccination) could potentially be useful in the identification of individuals at risk of experiencing ADEs. 5 M. Lam, 1 M. Egail, 1 A. J. Bedlow 1 and S. Tso 1

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine

Mechanisms underlying adverse reactions to vaccines

Vasculitis as an adverse event following immunization -systematic literature review

A transcriptomics data-driven gene space accurately predicts liver cytopathology and drug-induced liver injury

Jephson Dermatology Centre, South Warwickshire NHS Foundation Trust, Warwick, UK E-mail: simontso@doctors.org.uk Conflict of interest: the authors declare that they have no conflicts of interest. ML and ME contributed equally to this work and should be considered joint first authors. Accepted for publication 1 April 2021